Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $606.42M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.32M
Average 0.74M
DSGN Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Design Therapeutics, Inc.NASDAQ: DSGN
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $2.51M (cash outflow) rose 734.2% year over year, ahead of the +126.9% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -5.9% a year.
Context
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +734.2% holds above the trailing-twelve-month pace of +126.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 4.49M USD
- Year-over-year change
- +468.0%
- 4-year CAGR
- +16.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.49M | +468.0% |
| FY2024 | 2024-12-31 | (1.22M) | +2.2% |
| FY2023 | 2023-12-31 | (1.25M) | -123.1% |
| FY2022 | 2022-12-31 | 5.39M | +123.2% |
| FY2021 | 2021-12-31 | 2.41M | — |
Accounts Payables vs competitors
How DSGN compares with its peers on the latest reported figures
- DSGN's LTM Mar 2026 accounts payables of $2.28M is the 6th largest of the 11 companies compared; the peer median is $2.88M.
- Its year-over-year change of +126.9% is the 3rd highest of 10, against a peer median of -42.1%.
- Over three fiscal years its annual growth of -5.9% compares with a peer median of -10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $39.15M | -42.1% | -10.9% | 1.8% | |
| LTM Jun 2026 | $23.17M | +98.6% | — | — | |
| LTM Sep 2026 | $11.71M | -66.8% | — | 1.2% | |
| LTM Mar 2026 | $5.87M | +736.9% | +375.3% | — | |
| LTM Mar 2026 | $4.81M | +99.3% | — | 6.7% | |
| LTM Mar 2026 | $2.28M | +126.9% | -5.9% | — | |
| LTM Mar 2026 | $2.06M | -230.7% | -12.7% | — | |
| LTM Mar 2026 | $943K | +140.1% | — | — | |
| LTM Mar 2026 | $829K | -92.1% | +460.3% | 2.6% | |
| LTM Mar 2026 | $767K | -76.5% | -40.7% | — | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DSGN) | $2.88M | -42.1% | -10.9% | 1.8% | |
Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.53M) | (63.31M) | (66.86M) | (49.59M) | (69.79M) |
| Depreciation & Amortization | 129K | 406K | 537K | 596K | (2.63M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M |
| Change in Working Capital | 1.4M | 1.99M | 728K | (993K) | 3.11M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.41M | 5.39M | (1.25M) | (1.22M) | 4.49M |
| Other Working Capital | (1.02M) | (3.39M) | 1.97M | 226K | (1.38M) |
| Other Non-Cash Items | (58K) | (1.33M) | (6.05M) | (6.19M) | 406K |
| Operating Cash Flow | (29.38M) | (51.32M) | (58.56M) | (43.11M) | (54.36M) |
| Capital Expenditures | (1.54M) | (918K) | (256K) | (340K) | (193K) |
| Acquisitions (Net) | 52.11K | 39K | 0 | 0 | 0 |
| Purchases of Investments | (86.26M) | (313M) | (224.7M) | (230.18M) | (291.78M) |
| Sales of Investments | 34.16M | 92.89M | 277.5M | 274.47M | 314.89M |
| Other Investing Activities | (52.11K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (53.64M) | (220.99M) | 52.54M | 43.96M | 22.91M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 254.27M | 662K | 724K | 513K | 25.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 228K | (427K) | 0 | 0 | 0 |
| Financing Cash Flow | 379.21M | 235K | 724K | 513K | 25.74M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 296.19M | (272.07M) | (5.3M) | 1.36M | (5.71M) |
| Free Cash Flow | (30.92M) | (52.24M) | (58.82M) | (43.45M) | (54.55M) |
Design Therapeutics, Inc.
NASDAQ:DSGN
Intrinsic Alpha fair value
Locked
Current Price
$9.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.